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Poster Session II 121(range 0.2 – 68 months) with 32% (12 patients) remaining alive at
time of analysis. Sustained donor engraftment (neutrophils) oc-
curred in 33 (89%) patients. The median time to neutrophil en-
graftment was 14 days (range 9–27); and for platelet engraftment
19 days (range 13–67). The median length of stay in hospital was
28 days (range 15–71). Twenty eight out of 37 patients (76%)
were discharged from hospital post transplant. Nine patients
(24%) required an Intensive Care admission. Seventeen out of
the 37 patients (46%) had severe mucositis requiring opiates,
with 6 requiring total parental nutrition. Graft vs Host Disease
(GVHD) occurred in 24 individuals; 42% had acute GVHD
(50% had .5 Grade 3 severity) and 55% had chronic GVHD
(44% moderate to severe). The day 100 transplant-related mor-
tality (TRM) was 32%, with the overall (all cause) mortality at
1 year of 51%. GVHD accounted for 6 (24%) deaths, primary
disease 7 (28%) and sepsis 12 (48%). Conclusion: The combina-
tion of Fludarabine/Melphalan as a reduced intensity conditioning
regime in this group of patients with advanced haematological ma-
lignancies can lead to prolonged disease control in up to one third of
patients. However, it is not without its short term and long term
toxicity, and is associated with a high day 100 transplant related
mortality.328
ALLOGENEIC TRANSPLANTATION IN RAPID SUCCESSION FROM TWO
DONORS: IMMUNOLOGIC LESSON FOR STEM CELL ENGRAFTMENT
Zuckerman, T., Haddad, N., Katz, T., Gidoni, O., Faibish, T.,
Rowe, J.M. Rambam Medical Center, Haifa, Israel.
A 40-year old female was diagnosed with stage II Hodgkin disease
in 1998. She was treated with standard therapy, relapsed and under-
went autologous stem cell transplantation (SCT). Two years later
she developed primary CNS B cell diffuse large cell lymphoma,
was treated, relapsed systemically and underwent a second autolo-
gus SCT. Two years later she relapsed again and received various
therapies with partial response. In February 2006 she underwent
matched unrelated donor (MUD) SCT with reduced intensity pro-
tocol containing fludarabine 200 mg/m2 and melphalan 140 mg/m2.
GVHD prophylaxis consisted of cyclosporine and a short course of
methotrexate. Donor (female) peripheral blood cells (7.7  106
CD34/kg) were collected in advance and cryopreserved. The cells
were transferred to a smaller freezing tank 24 hours before the
transplant. At the initiation of the transplant procedure the cells
were found to be completely thawed due to leaking tank. The cells
were infused and an aliquot was shown to have a viability of only
20%. The donor registry was contacted but the donor refused a fur-
ther donation at that time.
Hence, a second fully matched male donor was immediately lo-
cated and a BM (1.74  106 CD34 cells/kg) was given, remarkably,
5 days following the first stem cell infusion. No additional chemo-
therapy or immunosuppression was given. Fourteen days following
the 2nd stem cell transplantation the patient developed diffuse ery-
thematous rash, fever and watery diarrhea. Chimerism analysis
(PCR for STR) revealed presence of both donors and no evidence
of patient cells in peripheral blood (Table 1). I.V. solumedrolDays from
1st transplant
Days from
2nd transplant
Stem cell
source
Chimera
1st donor
%
Chimera
2nd donor
%
Fish Y
chromosome
%
18 13 PB2 56 44 ND1
27 22 BM3 42 58 46
33 27 BM 95 5 9
41 35 BM 100 0 1
1Not done.
2Peripheral blood.
3Bone marrow.(2 mg/kg) was started to treat a possible acute GVHD. Repeat anal-
ysis is described in [Table 1]. Unfortunately the patient remained
neutropenic with no evidence for neutrophil and megakaryocyte
precursors in BM. On day 42 from 1st transplant the patient received
CD34 positive stem cells boost (4.4  106cells/kg) from the same
first female donor, engrafted promptly after 7 days and became
transfusion independent. GVHD was not aggravated following
stem cell boost. The patient gradually stopped steroids and cyclo-
sporine and remains alive and well after all immunosuppressive
therapy.
In conclusion, it appears that: (a) Low number of viable and
thawed stem cells can survive and lead to engraftment. (b) Double
allogeneic transplant ultimately leads to selection of a single donor
as described for double cord-blood transplants.329
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SE-
VERE APLASTIC ANEMIA (SAA) USING A NON-MYELOABLATIVE CONDI-
TIONING REGIMEN (NMCR)
Rosenthal, J., Pawlowska, A., Bolotin, E., Falk, P., Oliver, C.,
Forman, S. City of Hope National Medical Center, Duarte, CA.
Allogeneic bone marrow transplantation (ALLO BMT) is a cura-
tive treatment for patients (pts) with acquired SAA. Current prepar-
ative therapies are associated with early and late sequelae such as
organ injury, and secondary malignancies. We report the use of
NMCR in patients with SAA.
Patients andMethods: Four pts, ages 6–12 years, with SAA, had
ALLO BMT from an HLA-identical sibling (SIB) (n 5 2) or
a matched unrelated donor (MUD) (n 5 2). The reasons to offer
NMCR were: delay in results of chromosome fragility studies, ab-
normal pulmonary function, history of recent life threatening infec-
tion, and failure to respond to immunosuppressive therapy. The
NMCR consisted of fludarabine (FLU) (30 mg/m2  4), low dose
cyclophosphamide (LDC) (5 mg/kg  4) and rabbit antithymocyte
globulin (rATG) (1.5 mg/kg  4) in patients with SIB donor and
FLU, LDC, at 15 mg/kg  4, rATG and a single fraction of total
body irradiation at 200 cGy in patients with a MUD donor. Re-
sults: The NMCR was well tolerated in all 4 patients. Two pts
who had a SIB BMT had no transplant-related toxicities, including
mucositis or alopecia. Toxicities in the MUD BMT pts included
mild mucositis and partial alpecia in both pts. One pt (Pt#3) had re-
activation od Enterobacter cloacae sepsis with typhlitis and later
CMV viremia. Myeloid and platelet engraftment were uneventful
in 3 pts. The recovery of peripheral blood counts was slow in Pt
#3 following typhlitis and CMV viremia. Myeloid engraftment oc-
curred on day119 (range 15–33 days). The median time to a platelet
count.20,000 unsupported by transfusion was day133, (range 12–
76 days). Periodic engraftmen anlyses using short tandem repeat
(STR) by PCR continue to show full donor chimerism in all 4
pts. Acute GvHD of the skin was recorded only in the 2 pts with
MUD BMT. One patient had limited chronic GvHD (Pt#3). Three
pts. continue to do well with a fully recovered hematopoietic system
at 44, 19 and 5 months post transplant, respectively. Pt #3 had a slow
recovery of her peripheral counts but is transfusion independent for
greater than 2 months and doing well 7 months post-transplant.
Conclusion: This data suggests that a non-myeloablative, immu-
nosuppressive regimen is sufficient to provide a stable engraftment
in the patients with SAA. This approach may be associated with de-
creased transplant-related, short- and long-term, toxicities. A larger
study is needed to fully evaluate the outcome and the toxicity asso-
ciated with this conditioning.330
RITUXIMAB IS FEASIBLE TO ADMINISTER TO ALLOGRAFT RECIPIENTS
WITH ADVANCED CD201 MALIGNANCIES AND DOES NOT AFFECT
TIMELY HEMATOPOIETIC ENGRAFTMENT
Kharfan-Dabaja, M.A.1, Tate, C.1,2, Perkins, J.1, Fernandez, H.F.1,
Field, T.1, Ayala, E.1, Perez, L.1, Raychaudhuri, J.1, Alsina, M.1,
Ochoa-Bayona, L.1, Sullivan, D.1, Brand, L.1, Poling, W.1,
122 Poster Session IIAnasetti, C.1. 1H. Lee Moffitt Cancer Center and University of South
Florida, Tampa, FL; 2H. Lee Moffitt Cancer Center and University of
South Florida, Tampa, FL.
There is limited data evaluating the feasibility of combining rit-
uximab with conditioning chemotherapy (or chemo-radiotherapy)
for patients undergoing allogeneic hematopoietic cell transplanta-
tion (allo-HCT). Twelve patients (M 5 7; F 5 5), with median
age of 54.5 (41–66) years, underwent allo-HCT for the following
diagnoses (disease-status at transplantation) [chronic lymphocytic
leukemia (CLL)5 7 (CR2 5 2; PR2 5 3; $PR3 5 2); mantle cell
lymphoma (MCL)5 3 (CR1 5 1; $PR2 5 2); follicular NHL 5 1
(CR3 5 1), diffuse large B-cell (DLBC) NHL 5 1 (.PR3 5 1)].
Donors were as follows: matched-related donors (MRD) 5 7;
matched-unrelated donors (MUD) 53; mismatched donor
(MMD)5 2. Fludarabine-based regimens comprised fludarabine
plus targeted doses of intravenous busulfan (FLU-BU 5 8), or to-
tal-body irradiation (FLU-TBI 5 3), or cyclophosphamide (FLU-
CY 5 1). Anti-thymocyte glogulin (ATG) was administered in
MMD cases. GVHD prophylaxis consisted of tacrolimus plus my-
cophenolate mofetil5 8, or methotrexate5 4. Nine (75%) patients
received rituximab 375 mg/m2 on days11 (63 days) and all (100%)
received rituximab 375 mg/m2 on day18 (63 days) without serious
infusion reactions. All patients engrafted. Median time to neutro-
phil engraftment for entire cohort was 15.5 (12–21) days. Median
time to platelet engraftment in 8 patients was 13.5 (10–18) days.
Four patients never dropped their platelet counts below 20,000/
uL. Median donor chimerism at day 190 (610 days) for unsorted
BM, CD3 and CD33 by PCR/STR were 95% (70–100%), 87.5%
(59–100%) and 100%, respectively. At a median follow-up of 6
(2.2–32) months, the 100-day non-relapse mortality in 11 evaluable
patients was 10%. Acute GVHD, grades II, III, IV, developed in
58%, 8.3% and 8.3%, respectively, at a median of 28 (16–77)
days. Response rates, at day1100 (610 days), according to diagno-
sis, in 10 evaluable patients were as follows: CLL (CR5 4/5; PR5
1/5); MCL: (CR5 3/3); follicular NHL (CR5 1/1); DLBC: (pro-
gressive disease 5 1/1). Administration of rituximab is feasible and
does not affect timely hematopoietic engraftment in allo-HCT re-
cipients with advanced CD201 malignancies.331
EFFECT OF SMOKING ON MOBILIZATION OF HEMATOPOIETIC STEM
CELLS IN HEALTHY DONORS
Panwalkar, A.1, Devetten, M.2, Loberiza, F.3, Moehr, M.4,
Kessinger, A.5. 1University of Nebraska Medical Center, Omaha, NE;
2University of Nebraska Medical Center, Omaha, NE; 3University of
NebraskaMedical Center, Omaha, NE; 4University of NebraskaMedical
Center, Omaha, NE; 5University of Nebraska Medical Center, Omaha,
NE.
Background: Peripheral blood hematopoietic stem cells (PBSC)
mobilized with granulocyte colony stimulating factor (G-CSF) are
increasingly used for hematopoietic rescue in transplant proce-
dures. G-CSF mobilization results in adequate PBSC collection
in most healthy donors after 1 or 2 apheresis procedures. However,
factors affecting mobilization have not been elucidated. A recent
study showed that smoking cessation was associated with a rapid in-
crease in circulating vascular endothelial progenitor cells (VEPC) in
peripheral blood. Hence, we evaluated the effect of smoking on
PBSC mobilization. Methods: All healthy donor PBSC collections
at our center were included. Data on donor age, sex, weight, G-CSF
dose and schedule, total CD341 cells collected and time to engraft-
ment, were reviewed. Data on smoking were categorized as current,
past and never smokers. Poor mobilization was defined as collection
of less than 2  106 CD341 cells/kg after a single apheresis proce-
dure processing 10 liters of blood.Results: 368 healthy donors were
included from 1993 to 2007. Of these, 192 (52%) never smoked, 92
(25%) were current smokers, 59 (16%) were past smokers and the
status of 25 (7%) was unknown. 122 (33%) healthy donors were
found to be poor mobilizers by our definition. Distribution of cur-
rent, past and never smokers was similar between good and poor
mobilizers (p 5 0.34). There was no significant difference between
poor mobilization and current, past or never smoking status.However, a small effect trending toward poorer mobilization
amongst current smokers (p 5 0.20) versus never/past smokers
and ever smokers (p 5 0.15) versus never smokers was identified.
Poor mobilization was related to delayed engraftment (p 5 0.03).
We failed to detect significant association between smoking history
and time to engraftment. Conclusions: Smoking seems to have
a small, if any, impact on mobilization of hematopoietic stem cells.
The lack of significant effect of smoking may be due to several rea-
sons:
- Effects of smoking may be more pronounced in the steady state.
- Stimulation by growth factors (G-CSF) may have blunted this ef-
fect.
- Effect of smoking on the stem cells and marrow stroma may be
more pronounced in diseased individuals (i.e. autologous donors).
This study was limited to healthy donors.
- Smoking may have a differential effect on VEPC versus hemato-
poietic stem cells.
Studies on PBSC mobilization in individuals undergoing autolo-
gous transplant may shed further light on this issue.332
ALEMTUZUMAB (ALEM) AND CONTINUOUS-INFUSION PENTOSTATIN
(PENTO): A NOVEL NONMYELOABLATIVE (NM) PREPARATIVE REGI-
MEN FOR ALLOGENEIC (ALLO) HEMATOPOIETIC CELL TRANSPLANTA-
TION (HCT)
Klinkhammer, T.A., Carroll, M.P., Lambert, M.L., Fung, F.K.,
Cantu, E., Diaz, G., Trevor, K., Yeager, A.M. Arizona Cancer Center,
University of Arizona, Tucson, AZ.
Current NM preparative regimens for allo HCT consistently
cause significant post-HCT neutropenia and thrombocytopenia.
To test the hypothesis that pre-HCT immunosuppression alone al-
lows engraftment without significant myelosuppression, we are
evaluating a preparative regimen of continuous-infusion PENTO
(12 mg/m2 over 72 hr, days -8 through -6) and ALEM (20 mg/
day, days -5 through -1) for allo HCT in high-risk patients (pts)
with hematologic malignancies. To date, 5 pts (median age, 64 yr;
range, 54–69 yr) with AML (3 pts), CLL (1 pt), or multiple myeloma
(MM) (1 pt) have been enrolled on this trial; 2 pts (1 AML, 1 MM)
had failed previous autologous HCT. The median interval between
most recent conventional chemotherapy (chemoRx) and allo HCT
was 3 (range, 2–5) mo. All pts received G-CSF mobilized PBSCs
from 8/8 HLA-matched unrelated donors; median cell doses were
2.86 (range, 1.86–6.0)  106 CD341 cells/kg and 3.33 (range,
1.57–4.46)  108 CD31 cells/kg. Cyclosporine (CSA) was used
for GVHD prophylaxis. All pts had asymptomatic transient eleva-
tions of AST and ALT (CTCAE grade 2–3) between days -6 and
-2. Median duration of hospitalization post-HCT was 6 (range,
3–62) days. The median nadir of absolute neutrophil count was
0.75 (range, 0.18–1.42)  109/L at a median of day 116 (range,
day 111-day 121), and the median nadir of platelet count was 46
(range, 18–183)  109/L at a median of day 16 (range, day 11-
day 119). In contrast, the nadir of absolute lymphocyte count
(ALC) was 0 in all pts at a median of day 12 (range, day 0-day
112); at day 128, the median ALC was only 0.096 (range, 0.055–
0.32)  109/L. One pt developed grade II acute GVHD at day
121. Two pts had asymptomatic CMV reactivation at days 15
and111, respectively. At day128, bone marrow chimerism studies
showed a median of 27% (range, 13–100%) donor DNA. At day
1100, 3 of 4 evaluable pts had 38%, 84% and 100% donor chime-
rism, respectively; the pt with 38% donor DNA had recurrent MM,
and upon cessation of CSA, donor chimerism increased to 64% by
day 1124. One pt had no donor engraftment at day 1100 and had
the longest interval (5 mo) between conventional chemoRx and allo
HCT. Four pts are alive at a median of 1591 days (range, 461-2561)
after HCT; one pt with AML relapsed and died of GVHD after
a second allo HCT. These encouraging results suggest that immu-
nosuppression with PENTO and ALEM is a novel NM HCT strat-
egy that allows donor cell engraftment without significant
myelosuppression.
